Craig Parker
Fortune : 476 367 $ au 31/05/2026
Fortune : 476 367 $ au 31/05/2026
Craig C.
Parker was the founder of Vega Therapeutics, Inc., founded in 2009, where the title held was Chief Executive Officer from 2009 to 2011.
Current jobs include President, Chief Executive Officer & Director at Surrozen Operating, Inc. since 2018; President, Chief Executive Officer & Director at Surrozen, Inc. since 2018; Chairman-Leadership Council at the University of Michigan since 2005; and Venture Partner at The Column Group LLC since 2024.
Former jobs include Managing Director at Lehman Brothers, Inc.; Director at Gryphon Therapeutics, Inc.; Independent Director at vTv Therapeutics, Inc. from 2015 to 2019; Senior Vice President & General Manager at Immunex Corp.
from 1999 to 2001; Senior VP-Strategy & Corporate Development at Human Genome Sciences, Inc. from 2011 to 2012; EVP-Corporate Development & Scientific Affairs at Geron Corp.
in 2014; Chief Financial Officer at Proteolix, Inc. from 2012 to 2013; and Senior VP-Corporate Development at Jazz Pharmaceuticals Plc from 2014 to 2018.
Education includes an MBA from Stephen M.
Ross School of Business, an undergraduate degree from The University of Chicago conferred in 1985, and an MBA from the University of Michigan conferred in 1993.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SURROZEN INC 0,16 % | 15/06/2026 | 18 175 ( 0,16 % ) | 476 367 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| SURROZEN, INC. | Directeur Général | 01/03/2018 |
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Discovers and develops novel regenerative medicines | Directeur Général | 04/04/2018 |
University of Michigan
University of Michigan Other Consumer ServicesConsumer Services Functions as a College/University | Président | - |
The Column Group LLC
The Column Group LLC Investment ManagersFinance TCG invests in companies located in the United States. The firm focuses on drug discovery, biology, chemistry, and technology sectors. It provides financing for early and later stage capital requirements with an investment size of USD 50 - 60 million. | Private Equity Investor | 01/06/2024 |
| Sociétés | Poste | Fin |
|---|---|---|
| VTV THERAPEUTICS INC. | Directeur/Membre du Conseil | 01/02/2019 |
| JAZZ PHARMACEUTICALS PLC | Corporate Officer/Principal | 01/03/2018 |
| GERON CORPORATION | Directeur Technique/Scientifique/R&D | 31/07/2014 |
Proteolix, Inc.
Proteolix, Inc. Pharmaceuticals: MajorHealth Technology Manufactures bio-pharmaceutical related products | Directeur Financier/CFO | 26/11/2013 |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Provides pharmaceutical and diagnostic products | Corporate Officer/Principal | 03/08/2012 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 15 |
|---|---|
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Manufactures, markets, and researches therapeutic products | Health Technology |
Lehman Brothers, Inc.
Lehman Brothers, Inc. Investment Banks/BrokersFinance Provides investment banking services | Finance |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Provides pharmaceutical and diagnostic products | Health Technology |
Geron Corp.
Geron Corp. BiotechnologyHealth Technology Discovers and develops therapeutic products for cancer | Health Technology |
Gryphon Therapeutics, Inc.
Gryphon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and produces protein therapeutics | Health Technology |
The University of Chicago
The University of Chicago Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Michigan
University of Michigan Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Proteolix, Inc.
Proteolix, Inc. Pharmaceuticals: MajorHealth Technology Manufactures bio-pharmaceutical related products | Health Technology |
The Column Group LLC
The Column Group LLC Investment ManagersFinance TCG invests in companies located in the United States. The firm focuses on drug discovery, biology, chemistry, and technology sectors. It provides financing for early and later stage capital requirements with an investment size of USD 50 - 60 million. | Finance |
Stephen M. Ross School of Business
Stephen M. Ross School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Jazz Pharmaceuticals Plc
Jazz Pharmaceuticals Plc Pharmaceuticals: MajorHealth Technology Engages in the development and commercialization of pharmaceutical products to treat neurological disorders | Health Technology |
Vega Therapeutics, Inc.
Vega Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Engagers in R&D and manufactures antibodies that targets proteins | Health Technology |
vTv Therapeutics, Inc.
vTv Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage pharmaceutical company which engages in discovery and development of orally administered small molecule drugs for treating metabolic and inflammatory disorders | Health Technology |
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Discovers and develops novel regenerative medicines | Health Technology |
Surrozen, Inc.
Surrozen, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that discovering and developing drug candidates | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national